1. Quality of life after definitive linear accelerator-based stereotactic radiotherapy for prostate cancer: a longitudinal study
- Author
-
Hideomi Yamashita, Mami Ogita, Subaru Sawayanagi, Yuki Nozawa, and Osamu Abe
- Subjects
Stereotactic body radiotherapy ,Prostate cancer ,Quality of life ,Patient-reported outcomes ,Radiation therapy ,Medical physics. Medical radiology. Nuclear medicine ,R895-920 ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Abstract
Abstract Background Prostate cancer is the second most common malignancy worldwide, and the majority of patients are diagnosed with localized disease. We examined patients’ quality of life after stereotactic body radiation therapy (SBRT) for prostate cancer. Methods We included patients who were treated between 2016 and 2020. Inclusion criteria were adenocarcinoma of the prostate; class risk of low, intermediate, and high; and a World Health Organization performance status of 0–2. Quality of life was measured using the Functional Assessment of Cancer Therapy-Prostate (FACT-P). Results A total of 439 patients were treated with SBRT, with a median age of 73 years old. The median follow-up period was 34 months. FACT-P Trial Outcome Index (p
- Published
- 2022
- Full Text
- View/download PDF